Inclusion Criteria:

          -  Advanced-stage (overall stage III and IV) head and neck cancers (sinonasal oral
             cavity, oropharynx, larynx, and hypopharynx) undergoing surgical resection and then
             adjuvant therapy. Primary and recurrence cases are acceptable

          -  Karnofsky performance status of >= 80

          -  Hemoglobin >= 10 g/dL

          -  Total bilirubin =< 2 mg/dL

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 2.5 x institutional upper limit of normal (ULN)

          -  Albumin > 3.5 g/dL

          -  Estimated glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m^2 or creatinine
             clearance >= 30 mL/min by Cockcroft-Gault

          -  Serum potassium within normal limits

          -  Negative serum or urine pregnancy test at screening for women of childbearing
             potential

          -  Highly effective contraception for female subjects throughout the study and for at
             least 5 days after the last dose of study therapy if the risk of conception exists

          -  Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events
             (CTCAE) version (v)5.0 from toxicities related to any prior treatments, unless AE(s)
             are clinically nonsignificant and/or stable on supportive therapy

          -  Willing to maintain a diary of all opioids used during the trial for the treatment of
             pain

          -  Able to provide informed consent and willing to sign an approved consent form that
             conforms to federal and institutional guidelines

        Exclusion Criteria:

          -  Known metastatic disease or the tumor is deemed not surgically resectable

          -  Established in a pain management clinic or has taken opioids regularly >= 6 months

          -  Known or suspected to be poor CYP2C9 metabolizers based on previous history/experience
             with other CYP2C9 substrates (such as warfarin, phenytoin)

          -  Known hypersensitivity to celecoxib, aspirin, other non-steroidal anti-inflammatory
             drug (NSAID)s, or sulfonamides

          -  Uncontrolled hypertension defined as blood pressure (BP) > 150 mmHg systolic or > 90
             mmHg diastolic on three consecutive reads, taken in one sitting despite optimal
             antihypertensive treatment

          -  Patients with a known history of the following:

               -  Cerebrovascular accident (CVA), stroke, or cardiovascular thrombotic events (e.g.
                  acute myocardial infarction).

               -  Chronic heart failure.

               -  Gastrointestinal bleeding, ulceration, peptic ulcer disease, or perforation of
                  the stomach or intestines.

               -  Aspirin-sensitive asthma.

               -  Chronic kidney disease, stage 4 or 5

          -  Patients with a prior or concurrent malignancy whose natural history or treatment has
             the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial

          -  The subject has uncontrolled, significant intercurrent or recent illness requiring
             systemic therapy, would preclude safe study participation, or is deemed clinically
             significant by the investigator

          -  Known human immunodeficiency virus (HIV) infection with a detectable viral load within
             6 months of the anticipated start of treatment.

               -  Note: Patients on effective anti-retroviral therapy with an undetectable viral
                  load within 6 months of the anticipated start of treatment are eligible for this
                  trial

          -  Known chronic hepatitis B virus (HBV) or hepatitis C virus infection with a detectable
             viral load.

               -  Note: Patients with an undetectable HBV viral load on appropriate suppressive
                  therapy are eligible. Patients with an undetectable hepatitis C virus (HCV) viral
                  load on appropriate treatment are eligible

          -  Subjects taking prohibited medications . A washout period of prohibited medications
             for a period of at least 5 half-lives or as clinically indicated should occur prior to
             the start of treatment